PT - JOURNAL ARTICLE AU - Clemenceau, Jean R. AU - Lee, Sung Hak AU - Bazeley, Peter AU - Millinovich, Alex AU - Jin, Jian AU - Pennell, Nathan AU - Sohal, Davendra AU - Hwang, Tae Hyun TI - Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute Study AID - 10.1101/19013433 DP - 2019 Jan 01 TA - medRxiv PG - 19013433 4099 - http://medrxiv.org/content/early/2019/12/04/19013433.short 4100 - http://medrxiv.org/content/early/2019/12/04/19013433.full AB - IMPORTANCE The role of Tumor Mutation Burden (TMB) as a prognostic and/or predictive biomarker for Immune Checkpoint Blockade (ICB) therapy in a real-world clinical setting is still unclear.OBJECTIVE To assess whether TMB status provided by a clinically and commercially available tumor genomic profiling (TGP) assay is associated with overall survival of Non-Small Cell Lung Cancer (NSCLC) patients treated with ICB from a single institute.DESIGN, SETTING, AND PARTICIPANTS Outcomes and genetic testing data were collected for 188 NSCLC patients treated within the Cleveland Clinic system between August 2012 and July 2017.MAIN OUTCOMES AND MEASURES Overall survival (OS) from time receiving ICB therapy.RESULTS Among 188 patients with NSCLC (median age, 62 years; 49.5% female), 86 (45.7%) received ICB therapy. Patients were grouped into three categories based on the status of TMB (in mutations/Mb): high (>= 20/Mb), intermediate (>=5 to <= 20/Mb), and low (<5/Mb). In patients treated with ICB, TMB high status was not significantly associated with improved OS from therapy initiation (HR: 0.90 [95% CI, 0.52-2.49, P>0.8], median OS difference: 9.7 months).CONCLUSIONS AND RELEVANCE Among patients with NSCLC from a single institute in a longitudinal database of clinical data including TGP results, exploratory analyses do not show statistical significance for the prognostic utility of TMB. These findings indicate that there is a need for more prospective data on the use of TMB status as a guide for ICB therapy in a routine care setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.